(Q36562248)

14 August 2017

1 reference

title

Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events (English)

1 reference

14 August 2017

author

Christie M. Ballantyne

series ordinal

2

object named as

Christie M Ballantyne

1 reference

14 August 2017

Vijay Nambi

1

1 reference

14 August 2017

publication date

1 September 2006

1 reference

Current Atherosclerosis Reports

14 August 2017

published in

1 reference

14 August 2017

volume

8

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

374-381

1 reference

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0034-8

The expanding superfamily of phospholipase A(2) enzymes: classification and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0034-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0034-8

Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0034-8

A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0034-8

Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis

21 January 2018

1 reference

12 December 2020

Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia

1 reference

12 December 2020

N-linked glycosylation of macrophage-derived PAF-AH is a major determinant of enzyme association with plasma HDL.

1 reference

12 December 2020

Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.

1 reference

12 December 2020

Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.

1 reference

12 December 2020

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study

1 reference

12 December 2020

Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study

1 reference

12 December 2020

PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme

1 reference

12 December 2020

Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase A2) to the ankle-brachial index.

1 reference

12 December 2020

Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-).

1 reference

12 December 2020

The effect of statin therapy on lipoprotein associated phospholipase A2 levels

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke

1 reference

12 December 2020

Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

1 reference

12 December 2020

Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice

1 reference

12 December 2020

Involvement of PAF in atherogenesis. Brief review

1 reference

12 December 2020

The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma

1 reference

12 December 2020

Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

LDL- is a lipid hydroperoxide-enriched circulating lipoprotein.

1 reference

12 December 2020

Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease

1 reference

12 December 2020

Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.

1 reference

12 December 2020

Platelet-activating factor acetylhydrolases

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 as a target of therapy

1 reference

12 December 2020

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

1 reference

12 December 2020

Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL.

1 reference

12 December 2020

Human platelets release a paf-acether: acetylhydrolase similar to that in plasma

1 reference

12 December 2020

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

1 reference

12 December 2020

A cytotoxic electronegative LDL subfraction is present in human plasma

1 reference

12 December 2020

Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.

1 reference

12 December 2020

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

1 reference

12 December 2020

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor

1 reference

12 December 2020

Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis

1 reference

12 December 2020

Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease

1 reference

12 December 2020

Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle

1 reference

12 December 2020

Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells

1 reference

12 December 2020

Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase

1 reference

12 December 2020

Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells.

1 reference

12 December 2020

SB-480848. GlaxoSmithKline.

1 reference

12 December 2020

Platelet-Activating Factor Acetylhydrolase Is Mainly Associated With Electronegative Low-Density Lipoprotein Subfraction

1 reference

12 December 2020

Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor

1 reference

12 December 2020

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy

1 reference

12 December 2020

Molecular Basis of the Interaction between Plasma Platelet-activating Factor Acetylhydrolase and Low Density Lipoprotein

1 reference

12 December 2020

Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma

1 reference

12 December 2020

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

1 reference

12 December 2020

Isolation, Characterization, and Functional Assessment of Oxidatively Modified Subfractions of Circulating Low-Density Lipoproteins

1 reference

12 December 2020

Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe

1 reference

12 December 2020

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes

1 reference

12 December 2020

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals

1 reference

12 December 2020

L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion.

1 reference

12 December 2020

10.1007/S11883-006-0034-8

Identifiers

DOI

1 reference

14 August 2017

1 reference